Unlock measurable value at every stage of the clinical development and commercialization journey.
Discover our award-winning AI, digital innovation, and healthcare marketing initiatives.
Formulate your life sciences strategy. Where to play. How to win.
Define and refine your strategy at the product, franchise, business unit, therapeutic area, and portfolio levels.
We help life sciences leaders identify where future growth could come from, determine which opportunities to pursue, and make confident strategic choices about where to play and how to win.
Bringing together scientific, clinical, commercial, Medical Affairs, pricing and access expertise with data and AI-enabled intelligence, we help teams challenge assumptions, build a shared evidence base, and turn complex opportunities into clear strategic decisions.
In fast-evolving markets, future sources of value may not yet be obvious. Identifying and prioritizing emerging signals early can help you shape the portfolio before the landscape shifts.
When there are more possibilities than capital or capacity to pursue them, leaders need to distinguish attractive opportunities from those that warrant investment and organizational focus.
Scientific, clinical, commercial and access teams can interpret the same evidence differently. Creating a shared view of the evidence helps leadership focus on the trade-offs that matter.
Combine strategic foresight, deep therapeutic expertise and AI-enabled intelligence to identify emerging sources of growth and define credible strategic options.
Surface and challenge assumptions, bringing together cross-functional evidence and expertise to pressure-test opportunities from every angle.
Build a shared evidence base and bring trade-offs across opportunities, assets and investment priorities into focus, enabling clearer, more confident portfolio decisions.
As President of Putnam, Matt leads a team focused on strategic acuity and patient impact. He has partnered with global biopharma across therapeutic areas from pipeline shaping to launch, applying structured thinking and objective analysis to drive results.
Mariah translates insights from primary and secondary research into clear strategic guidance across neurology, rare diseases, oncology, and vaccines. She brings deep expertise in qualitative and quantitative methods and actionable insight development.
Varun is a physician who has been supporting biopharma clients as a strategy consultant for the past 15 years. His areas of focus are commercial strategy, growth strategy, medical affairs, and deals for life science companies worldwide.
John has 30+ years of strategy consulting experience, advising pharma and biotech executives on pricing, contracting, reimbursement, corporate strategy, product commercialization, clinical trial development, and sales force optimization.
John helps clients build clinical development and go-to-market strategies across therapy areas. He guides decisions on target profiles, clinical paths, competitive positioning, and opportunity sizing to support early-stage asset prioritization.
Kristen leads Putnam’s Global Commercial Practice, bringing deep expertise in corporate and commercial strategy across portfolio management, innovation, and commercialization. Her experience includes senior biopharma leadership roles and a prior tenure as a Putnam Partner.
AssetNav, part of Navigator AI™, evaluates, prioritizes, and scores assets or BD opportunities quickly and at scale. It solves incomplete or siloed data that delay opportunity evaluation. A pre-built, configurable Inizio team enabler for clinical development, BD&L, and early commercial strategy, it uses proprietary algorithms to inform smarter BD&L and portfolio decisions.
Access the most up-to-date health and life sciences insights and resources.
In pharma commercialization, AI and analogs set the stage, but human insight drives strategies that break precedent and win markets
In pharma commercialization, AI and analogs set the stage, but human insight drives strategies that break precedent and win markets
Explore a new model for antibiotic investment—driven by AMR, evolving P&R frameworks, and key indicators shaping commercial strategy.
Refined HCP targeting in rare disease using integrated data, boosting hit rates from 10% to 50% and delivering 3x ROI in 6 months.
Let’s discuss how we can help you.
